ERS Genomics Completes 45 CRISPR Licensing Deals To Date, Largely For Screening, Discovery
Executive Summary
Despite being ineligible to license its CRISPR technology for human gene and cell therapy applications, ERS is doing considerable business with biopharmas for internal R&D projects.
You may also be interested in...
If PTAB Backs Berkeley IP Holders' New Patent Claims, CRISPR Licensing Could Be Simplified
The USPTO's PTAB will determine whether UC-Berkeley or Broad Institute holders of CRISPR patents first invented its use in eukaryotic cells. The outcome could either benefit the Berkeley group, which could simplify licensing deals, or maintain the status quo.
Deal Watch: Sanofi Further Opts Out Of CNS Tie-Up With Voyager
Sanofi returns two partnered assets to Voyager, further unraveling 2015 deal. Celgene drops Mereo cancer candidate ahead of merger with Bristol, while Ultragenyx and Arcturus expand their joint rare disease efforts.
CRISPR/Cas9 Patent Battle: What's Happened, What's Next?
With the gene editing pipeline at stake, academic research institutions are battling for ownership of the foundational patents in CRISPR/Cas9 technology. A new report from Datamonitor Healthcare spells out the IP challenges and provides a timeline of key patent decisions.